Ochre Bio

Ochre Bio is developing RNA-based therapies for liver diseases by leveraging human liver data, AI-driven models, and in-house RNA platforms. The company combines human-derived datasets with AI to identify and validate drug targets, aiming to address chronic liver disease and reduce reliance on liver transplants.

Ochre Bio builds a platform that (1) creates comprehensive human liver data sets by integrating proprietary gene perturbation atlases with patient disease atlases to predict causal drug targets, (2) uses human validation models such as perfused livers, diseased tissue slices, and primary cells to model biological complexity at scale, and (3) internally develops RNA therapies to shorten RD cycle times from years to weeks. Their pipeline includes discovery, validation, lead development, and IND-enabling studies, with RNA therapies designed in-house (e.g., OB-220) and a focus on cytoprotection, metabolic disease (cirrhosis/MASH), and fibrosis indications.

Who it’s for: Pharmaceutical companies, biotech partners, and research organizations focused on chronic liver diseases seeking novel RNA-based therapeutics and human-data-driven drug discovery platforms.

Partner deals and AI-driven pact announcements with GSK, Boehringer Ingelheim, and other pharma companies; active news about collaborations and a funded platform